Institute of Cytology and Genetics, Novosibirsk, Russia.
Expert Rev Vaccines. 2010 Aug;9(8):947-55. doi: 10.1586/erv.10.67.
Human hepatitis B virus (HBV) causes a communicable disease that spreads worldwide and has brought about considerable economic losses due to human mortality and morbidity. HBV fails to reproduce in both cell cultures and laboratory animals; however, it is known that excess virion surface protein named hepatitis B surface antigen (HBsAg) is produced during viral replication and circulates in the blood of carriers as noninfectious particles of 22-nm diameter. It had been shown that purified HBsAg particles induce an efficient systemic immune response after injection. Consequently, subunit HBV vaccines based on HBsAg synthesized in yeasts or mammalian cell culture are currently used. Taking into account that hepatitis B is a sexually transmitted disease, development of a mucosal HBV vaccine would be beneficial. In this article, we analyze the data on development of plant-based HBV vaccines.
人乙型肝炎病毒(HBV)可引起一种传染性疾病,在全球范围内传播,并因人类的死亡率和发病率而造成相当大的经济损失。HBV 既不能在细胞培养物中繁殖,也不能在实验动物中繁殖;然而,已知在病毒复制过程中会产生过量的病毒表面蛋白,称为乙型肝炎表面抗原(HBsAg),并作为 22nm 直径的非传染性颗粒在携带者的血液中循环。已经表明,纯化的 HBsAg 颗粒在注射后会引发有效的全身免疫反应。因此,目前使用基于酵母或哺乳动物细胞培养物中合成的 HBsAg 的亚单位乙型肝炎疫苗。鉴于乙型肝炎是一种性传播疾病,开发黏膜乙型肝炎疫苗将是有益的。在本文中,我们分析了基于植物的乙型肝炎疫苗的开发数据。